Trials / Withdrawn
WithdrawnNCT04558580
Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures
A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of South Alabama · Academic / Other
- Sex
- All
- Age
- 12 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of Rufinamide in reducing seizure frequency in subjects with partial seizures not fully controlled despite treatment with 1 to 3 concomitant antiepileptic drugs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rufinamide | Rufinamide |
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2020-09-22
- Last updated
- 2020-09-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04558580. Inclusion in this directory is not an endorsement.